Citigroup reiterated coverage on MultiPlan with a new price target
$MPLN
Business Services
Consumer Discretionary
Citigroup reiterated coverage of MultiPlan with a rating of Buy and set a new price target of $7.00 from $9.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/26/2024 | $2.00 | Neutral | Piper Sandler |
| 12/13/2022 | $3.00 → $2.00 | Buy → Neutral | Citigroup |
| 7/12/2022 | $6.50 | Neutral | Goldman |
| 12/20/2021 | $9.00 → $7.00 | Buy | Citigroup |
| 11/11/2021 | $7.00 → $6.00 | Equal-Weight | Barclays |
| 10/4/2021 | $9.00 | Buy | Citigroup |
| 8/20/2021 | $9.00 | Buy | Tigress Financial |
10-K - Claritev Corp (0001793229) (Filer)
8-K - Claritev Corp (0001793229) (Filer)
8-K - Claritev Corp (0001793229) (Filer)
Piper Sandler initiated coverage of MultiPlan with a rating of Neutral and set a new price target of $2.00
Citigroup downgraded MultiPlan from Buy to Neutral and set a new price target of $2.00 from $3.00 previously
Goldman initiated coverage of MultiPlan with a rating of Neutral and set a new price target of $6.50
Latest agreement expands access to the PHCS and MultiPlan Networks ClearNote Health, a company focused on improving early detection for some of the deadliest cancers, today announced an agreement with Claritev, Inc. ("Claritev") (NYSE:CTEV), previously MultiPlan, Inc. (NYSE:MPLN), a technology and data insights company focused on making healthcare more affordable, transparent, and fair for all. As part of the agreement, ClearNote Health's Avantect® Pancreatic Cancer Test will now be available to health plan members accessing Claritev's national PHCS and MultiPlan Networks. While early detection has vastly improved survival rates for many types of cancer, pancreatic cancer is often diagnos
Q4 2024 Revenues of $232.1 million, Net Loss of $138.0 million and Adjusted EBITDA of $141.6 million Full Year 2024 Revenues of $930.6 million, Net Loss of $1,645.8 million and Adjusted EBITDA of $576.7 million Full Year 2025 Revenues guidance of (2)% to flat as compared to FY 2024 and FY 2025 Adjusted EBITDA % guidance of 62.5% to 63.5% Claritev Corporation ("Claritev" or the "Company") (NYSE:MPLN), formerly known as MultiPlan, a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today reported financial results for the fourth quarter and full year ended December 31, 2024. Chairman, CEO and President Travis Dalt
Claritev's Award-Winning Analytics Solution, BenInsights®, is Powered by Oracle Cloud and Now Available in the Oracle Cloud Marketplace Claritev Corporation ("Claritev" or the "Company") (NYSE:MPLN), formerly known as MultiPlan, a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, and an Oracle partner, announced today its analytics solution, BenInsights®, has achieved Integrated with Oracle Cloud Expertise and is now available in the Oracle Cloud Marketplace, offering added value to Oracle Cloud customers. The BenInsights platform enables visibility into benefit plan performance and compliance responsibilities for employers of
Tiffani Misencik Named Chief Growth Officer in New Executive Leadership Role MultiPlan Corporation ("MultiPlan" or the "Company") (NYSE:MPLN), a leading provider of data-driven cost management solutions that deliver transparency and promote fairness, quality and affordability to the U.S. healthcare industry, today announced a new addition to its executive leadership team to support the next phase of the Company's strategic growth. Tiffani Misencik has been appointed Chief Growth Officer. In this newly created role, Misencik will oversee MultiPlan's sales and revenue growth strategy across all market segments. She will lead the company's efforts in client acquisition, client management, an
MultiPlan Corporation (NYSE:MPLN) ("MultiPlan" or the "Company"), a leading provider of technology and data-enabled cost management, payment, and revenue integrity solutions to the U.S. health care industry, is honored to announce it has been named in the 2024 Fortune Best Workplaces in Health Care™ List. based on its 2023-2024 Great Place to Work® Certification™ results. This is the second time MultiPlan has been named in the Best Workplaces in Health Care list. Earning a spot means that MultiPlan is one of the best companies to work for in the country. The Best Workplaces in Health Care list is based on analysis of survey responses from over 185,000 employees from Great Place To Work Cer
MultiPlan Corporation ("MultiPlan" or the "Company") (NYSE:MPLN), a leading value-added provider of data analytics and technology-enabled end-to-end cost management, as well as payment and revenue integrity solutions to the U.S. healthcare industry, announced today its CFO transition plan and named Doug Garis as EVP and CFO, effective August 5, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240731993142/en/Doug Garis named EVP and CFO of MultiPlan (Photo: Business Wire) Jim Head, who has served as EVP and CFO of MultiPlan since November 2021, will transition to a Strategic Advisor role to the Company through the end of the
4 - MultiPlan Corp (0001793229) (Issuer)
4 - MultiPlan Corp (0001793229) (Issuer)
4 - MultiPlan Corp (0001793229) (Issuer)
4/A - MultiPlan Corp (0001793229) (Issuer)
4 - MultiPlan Corp (0001793229) (Issuer)
4 - MultiPlan Corp (0001793229) (Issuer)
Q4 2024 Revenues of $232.1 million, Net Loss of $138.0 million and Adjusted EBITDA of $141.6 million Full Year 2024 Revenues of $930.6 million, Net Loss of $1,645.8 million and Adjusted EBITDA of $576.7 million Full Year 2025 Revenues guidance of (2)% to flat as compared to FY 2024 and FY 2025 Adjusted EBITDA % guidance of 62.5% to 63.5% Claritev Corporation ("Claritev" or the "Company") (NYSE:MPLN), formerly known as MultiPlan, a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today reported financial results for the fourth quarter and full year ended December 31, 2024. Chairman, CEO and President Travis Dalt
MultiPlan Corporation ("MultiPlan" or the "Company") (NYSE:MPLN), a leading provider of technology and data solutions that improve affordability, quality and transparency in healthcare, announced today that it will release its fourth quarter and full year 2024 financial results on Tuesday, February 25, 2025, and hold its conference call that morning at 8:00 am Eastern Time. To join the conference call, please pre-register using the link below. Participants who pre-register will receive a calendar invitation with call access details including a unique pin. Pre-registration may be completed at any time up to and following the call start time. To pre-register, go to: https://www.netroadsho
– Q3 2024 Revenues of $230.5 million, Net Loss of $391.5 million (including a $361.6 million impairment of goodwill and indefinite-lived intangibles), and Adjusted EBITDA of $141.6 million – Identified potential medical cost savings of approximately $6.4 billion in Q3 2024, up 10% from Q3 2023 and up 3% from Q2 2024 MultiPlan Corporation ("MultiPlan" or the "Company") (NYSE:MPLN), a leading provider of data-driven cost management solutions that deliver transparency and promote fairness, quality and affordability to the U.S. healthcare industry, today reported financial results for the third quarter ended September 30, 2024 and updated its full-year 2024 guidance. CEO Travis Dalton said,
SC 13G/A - MultiPlan Corp (0001793229) (Subject)
SC 13G/A - MultiPlan Corp (0001793229) (Subject)
SC 13G/A - MultiPlan Corp (0001793229) (Subject)